Table 1

Baseline demographic and disease specific characteristics of patients on infliximab

N=291
Age35.0 (21.0)
Disease duration prior to IFX89.95 (157.2)
Montreal classification for Crohn’s, Age at diagnosis (years)
 A158 (19.9)
 A2197 (67.7)
 A336 (12.4)
Montreal classification for Crohn’s, Location
 L141 (14.1)
 L272 (24.7)
 L3177 (60.8)
 +L459 (20.4)
 +Perianal138 (47.4)
Montreal classification for Crohn’s, Behaviour
 B176 (26.1)
 B245 (15.5)
 B3170 (58.4)
Indication for IFX
 Luminal CD184 (63.2)
 Perianal CD55 (18.9)
 Luminal+perianal CD52 (17.9)
Previous exposure to biologic, n (%)24 (8.2)
Previous intestinal surgery, n (%)125 (43.0)
Era of IFX initiation, n (%)
 Pre-TDM161 (55.3)
 Post-TDM130 (44.7)
Patients tested for TDM, n (%)238 (81.8)
Median (range) number of TDMs per patient2 (0–8)
Interval from 1st infusion to 1st TDM (months)12.5 (30.2)
Undetectable levels episode, n (%)95 (40.1)
ATI episode, n (%)76 (31.9)
Dose intensification episode, n (%)62 (21.3)
Patients discontinued IFX due to SLR or SAE, n (%)109 (37.5)
Abdominal surgery after IFX initiation, n (%)44 (15.1)
Duration of overall follow-up (months)44.7 (40.3)
  • All values represent median (IQR) unless otherwise indicated. Time and duration is expressed in months.

  • ATI, antibodies to infliximab; CD, Crohn’s disease; IFX, infliximab; SAE, serious adverse event; SLR, secondary loss of response; TDM, therapeutic drug monitoring.